Onco Wiki / Regimen

Pembrolizumab monotherapy

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

ComponentsDRUG-PEMBROLIZUMAB
IDREG-PEMBROLIZUMAB-MONO
TypeRegimen
Statusreviewed 2026-05-04 | pending_clinical_signoff
DiseasesNone declared
SourcesNone declared

Used By

Disease

Indication